Expert Opinion on Drug Metabolism & Toxicology

Papers
(The H4-Index of Expert Opinion on Drug Metabolism & Toxicology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Probing the mechanism of reduced in vivo potency of insulin detemir105
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update52
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects52
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas45
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis44
Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance36
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury34
Hormones, microbes, and PrEP drugs in the female genital tract27
Guidance for interactions between antiseizure medications26
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata26
Comorbidities and the right dose: antipsychotics25
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury24
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria24
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine23
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database22
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis20
Bioactivity descriptors for in vivo toxicity prediction: now and the future19
Correction18
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer18
0.31164193153381